Presseaussendungen zu "Ema"

746 Aussendungen
vorige Seite Seite 1 von 50 nächste Seite

Theramex wird Intrarosa® in Europa, Australien, Russland und der Ukraine exklusiv von Endoceutics lizensieren

AUSSCHLIESSLICH FÜR EUROPÄISCHE WIRTSCHAFTSMEDIEN UND MEDIZINISCHE FACHPRESSE BESTIMMT

OTS0084
19.07.2018 12:18

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i]

OTE0001
29.06.2018 01:02

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin

OTE0004
23.06.2018 16:13

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg

m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

OTE0003
23.06.2018 16:10

Steba Biotech's VTP-Therapie mit TOOKAD® hält deutliche Verringerung der Gesamtprogression und Umstellung auf Radikaltherapie bei Patienten mit Prostatakrebs mit geringem Risiko nach 4 Jahren aufrecht

Steba Biotech, ein Biotechunternehmen in Privatbesitz, das auf die Entwicklung innovativer und minimalinvasiver photodynamischer Therapien und Systeme zur Behandlung von Krebs spezialisiert ist, gab heute …

OTS0004
22.06.2018 08:01

Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome …

OTE0001
12.06.2018 13:01
in Chronik

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018)

Serves Key Patient Populations Including, Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic, Inflammatory Diseases

OTE0003
07.06.2018 09:17

IMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients

To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched …

OTE0003
05.06.2018 14:01

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting

Wechsel an der Spitze des Pharma-Verbandes

Alexander Herzog wird neuer Generalsekretär der Pharmig.

OTS0036
29.05.2018 09:15

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise.

OTE0004
24.05.2018 08:03

Bioprojet und Harmony Biosciences, LLC geben bekannt: Pitolisant auf dem Weg zum US-amerikanischen Markt

FDA ERTEILT "FAST-TRACK"-ZULASSUNG SOWIE STATUS EINER "BREAKTHROUGH THERAPY" UND SCHLIESST ERSTE US-AMERIKANISCHE NARKOLEPSIE-PATIENTEN IM RAHMEN EINES ERWEITERTEN "ACCESS PROGRAMS" EIN

OTS0047
22.05.2018 10:03

Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein).

OTE0002
21.05.2018 11:47
vorige Seite nächste Seite